Evidence map›Paper›PMID 26505556›Full record

Trial reportGenetic testing and molecular biomarkers2015

The Frequency of Methylation Abnormalities Among Estonian Patients Selected by Clinical Diagnostic Scoring Systems for Silver-Russell Syndrome and Beckwith-Wiedemann Syndrome.

Mari-Anne Vals, Maria Yakoreva, Tiina Kahre, Pille Mee, Kai Muru, Kairit Joost, Rita Teek, Lukas Soellner, Thomas Eggermann, Katrin Õunap

Open access · greenAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Genetic testing and molecular biomarkers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Mari-Anne Vals1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Maria Yakoreva1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Tiina Kahre1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Pille Mee4 United Laboratories, Tartu University Hospital , Tartu, Estonia .
Kai Muru1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Kairit Joost1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Rita Teek1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Lukas Soellner5 Institute of Human Genetics , RWTH Aachen, Aachen, Germany .
Thomas Eggermann5 Institute of Human Genetics , RWTH Aachen, Aachen, Germany .
Katrin Õunap1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
Tartu University Hospital · EEUniversity of Tartu · EERWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo study the frequency of methylation abnormalities among Estonian patients selected according to published clinical diagnostic scoring systems for Silver-Russell syndrome (SRS) and Beckwith-Wiedemann syndrome (BWS). MATERIALS AND

methodsForty-eight patients with clinical suspicion of SRS (n = 20) or BWS (n = 28) were included in the study group, to whom methylation-specific multiplex ligation-dependant probe amplification analysis of 11p15 region was made. In addition, to patients with minimal diagnostic score for either SRS or BWS, multilocus methylation-specific single nucleotide primer extension assay was performed.

resultsFive (38%) SRS patients with positive clinical scoring had abnormal methylation pattern at chromosome 11p15, whereas in the BWS group, only one patient was diagnosed with imprinting control region 2 (ICR2) hypomethylation (8%). An unexpected hypomethylation of the PLAGL1 (6q24) and IGF2R (6q25) genes in the patient with the highest BWS scoring was found.

conclusionsCompared to BWS, diagnostic criteria used for selecting SRS patients gave us a similar detection rate of 11p15 imprinting disorders as seen in other studies. A more careful selection of patients with possible BWS should be considered to improve the detection of molecularly confirmed cases. Genome-wide multilocus methylation tests could be used in routine clinical practice as it increases the detection rates of imprinting disorders.

Indexed as

Beckwith-Wiedemann SyndromeCell Cycle ProteinsDNA MethylationReceptor, IGF Type 2Silver-Russell SyndromeTranscription FactorsTumor Suppressor ProteinsEstoniaFemaleHumansInfantInfant, NewbornMaleCell Cycle ProteinsPLAGL1 protein, humanReceptor, IGF Type 2Transcription FactorsTumor Suppressor Proteins

Identifiers

PMID26505556
PMCPMC4677517
OpenAlexW2253276515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.